Memory Enhancement in Aging With Optimal Dosing

April 1, 2026 updated by: Boston University Charles River Campus

Personalized Memory Enhancement in Aging: Pattern-Optimized tACS With Closed-Loop Precision Modulation

This project optimizes high-resolution tACS to improve memory in healthy older adults, advancing drug-free approaches for ADRD. We test stimulation schedules and develop an adaptive, brain-guided tACS system to strengthen memory-supporting networks.

Study Overview

Detailed Description

Cognitive decline, especially in memory and executive control, poses an escalating public health challenge as the population ages, contributing to loss of independence, reduced quality of life, and increased healthcare costs associated with Alzheimer's disease and related dementias (ADRD). Despite decades of research, there are few effective, non-pharmacological interventions capable of slowing or reversing these cognitive losses. Transcranial alternating current stimulation (tACS) has recently emerged as a promising, safe, and non-invasive technique for modulating neural rhythms that support memory. However, existing approaches remain limited by one-size-fits-all stimulation schedules that fail to account for individual brain connectivity patterns or dynamic fluctuations in cognitive state.

This project aims to advance precision neuromodulation for cognitive aging by optimizing and personalizing high-resolution tACS protocols to enhance memory in older adults. Building on strong pilot data demonstrating the feasibility of personalized and adaptive stimulation, we will use multimodal imaging (EEG and fMRI) to track changes in frontotemporal synchrony, specifically theta-gamma phase-amplitude coupling and theta phase synchronization, that are known to support memory formation and retrieval.

Aim 1 will establish how stimulation pattern (patterned vs. continuous waveforms) and schedule (one, three, or five consecutive days) shape the durability of memory enhancement. By comparing six systematically varied dosing protocols, we will determine the optimal pattern and repetition schedule that maximize and sustain improvements in working memory capacity, interference control, and long-term memory recognition over one month.

By integrating behavioral, electrophysiological, and neuroimaging measures with adaptive control algorithms, this research will identify reliable biomarkers of responsiveness, elucidate causal mechanisms linking neural synchrony to memory, and yield a new class of personalized, connectivity-guided interventions for cognitive decline. The findings will lay a foundation for scalable, non-invasive, and mechanism-driven treatments for ADRD and age-related memory loss, advancing the broader NIH mission of promoting healthy cognitive aging.

Study Type

Interventional

Enrollment (Estimated)

240

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Robert Reinhart, PhD
  • Phone Number: (617) 353-9481
  • Email: rmgr@bu.edu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • 65 years of age or older
  • normal or corrected-to-normal vision
  • color vision

Exclusion Criteria:

  • pregnant
  • metal implants in head
  • implanted electronic devices
  • history of neurological problems or head injury
  • skin sensitivity
  • claustrophobia
  • dementia (normal Montreal Cognitive Assessment > 25)
  • depression (normal Geriatric Depression Scale < 10)
  • history of psychosis
  • cognitive deficits (MoCA>25)
  • any psychoactive medication

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 1-day patterned tACS
Device: High definition transcranial electrical current stimulation Low-intensity, noninvasive application of electrical current to the human scalp with the goal of modulating levels of neuronal excitability.
Experimental: 3-day patterned tACS
Device: High definition transcranial electrical current stimulation Low-intensity, noninvasive application of electrical current to the human scalp with the goal of modulating levels of neuronal excitability.
Experimental: 5-day patterned tACS
Device: High definition transcranial electrical current stimulation Low-intensity, noninvasive application of electrical current to the human scalp with the goal of modulating levels of neuronal excitability.
Experimental: 1-day continuous tACS
Device: High definition transcranial electrical current stimulation Low-intensity, noninvasive application of electrical current to the human scalp with the goal of modulating levels of neuronal excitability.
Experimental: 3-day continuous tACS
Device: High definition transcranial electrical current stimulation Low-intensity, noninvasive application of electrical current to the human scalp with the goal of modulating levels of neuronal excitability.
Experimental: 5-day continuous tACS
Device: High definition transcranial electrical current stimulation Low-intensity, noninvasive application of electrical current to the human scalp with the goal of modulating levels of neuronal excitability.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Visual working memory capacity measured behaviorally
Time Frame: Baseline, 1-week after intervention, 1-month after intervention
Behavioral k-capacity estimate derived from the change-detection task
Baseline, 1-week after intervention, 1-month after intervention
Interruption suppression measured behaviorally
Time Frame: Baseline, 1-week after intervention, 1-month after intervention
Memory accuracy performance difference between interruption and control trials on the interruption working memory task
Baseline, 1-week after intervention, 1-month after intervention
EEG phase locking value (PLV) during working memory retention
Time Frame: Baseline, 1-week after intervention, 1-month after intervention
Phase locking value between frontotemporal EEG electrodes within the theta frequency band during the memory retention interval of the visual working memory task
Baseline, 1-week after intervention, 1-month after intervention
EEG phase amplitude coupling (PAC) during working memory retention
Time Frame: Baseline, 1-week after intervention, 1-month after intervention
Theta phase gamma amplitude cross-frequency coupling at temporal EEG electrodes during the memory retention interval of the visual working memory task
Baseline, 1-week after intervention, 1-month after intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2026

Primary Completion (Estimated)

January 31, 2031

Study Completion (Estimated)

January 31, 2031

Study Registration Dates

First Submitted

February 9, 2026

First Submitted That Met QC Criteria

March 6, 2026

First Posted (Actual)

March 10, 2026

Study Record Updates

Last Update Posted (Actual)

April 7, 2026

Last Update Submitted That Met QC Criteria

April 1, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 4230E_3

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Aging

Clinical Trials on 1-day patterned tACS

Subscribe